Host immunity in the protective response to nasal immunization with a pneumococcal antigen associated to live and heat-killed Lactobacillus casei

BMC Immunology

Volumn 12, Issue , 2011, Pages

  Vintiñi, Elisa O ^a,b   Medina, Marcela S ^a,b  

^a CENTRO DE REFERENCIA PARA LACTOBACILOS CERELA CONICET   (Argentina)

^b UNIVERSIDAD NACIONAL DE TUCUMÁN   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 4; PNEUMOCOCCUS VACCINE; PROBIOTIC AGENT; RECOMBINANT PNEUMOCOCCAL PROTECTIVE PROTEIN A; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; CYTOKINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL COUNT; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; INFECTION PREVENTION; LACTOBACILLUS CASEI; MALE; MOUSE; MUCOSAL IMMUNITY; NASAL LAVAGE; NONHUMAN; PNEUMOCOCCAL INFECTION; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; SURVIVAL; TH1 CELL; TH17 CELL; ANIMAL; BLOOD; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; METABOLISM; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, BACTERIAL; CYTOKINES; FEMALE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LACTOBACILLUS CASEI; MALE; MICE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 80051519195     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-12-46     Document Type: Article

References (53)

1. Scott JA. The global epidemiology of childhood pneumonia 20 years on. Bull World Health Organ 2008, 86:494-496. 2647465,2647465, 18568283.
2. Mulholland K. Childhood pneumonia mortality, a permanent global emergency. Lancet 2007, 21:285-289.
3. Lynch JP, Zhanel GG. Streptococcus pneumoniae: Epidemiology, Risk Factors, and Strategies for Prevention. Semin Respir Crit Care Med 2009, 30:189-209. 10.1055/s-0029-1202938, 19296419.
4. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, Butler JC, Rudolph K, Parkinson A. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007, 25:1784-1792.
5. Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 2008, 32:199-206. 10.1016/j.ijantimicag.2008.01.021, 18378430.
6. Godfroid F, Hermand P, Verlant V, Denoël P, Poolman J. Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect Immun 2010,
7. Rolo D, Ardanuy C, Fleites A, Martín R, Liñares J. Diversity of pneumococcal surface protein A (PspA) among prevalent clones in Spain. BMC Microbiol 2009, 6(9):80.
8. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11:S45-S53. 10.1038/nm1213, 15812489.
9. Maldonado Galdeano C, Perdigón G. The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity. Clin Vaccine Immunol 2006, 13:219-226. 10.1128/CVI.13.2.219-226.2006, 1391937, 16467329.
10. Ferreira D, Darrieux M, Silva DA, Leite LC, Ferreira JC, Ho PL, Miyaji E, Oliveira MS. Characterization of Protective Mucosal and Systemic Immune Responses Elicited by Pneumococcal Surface Protein PspA and PspC Nasal Vaccines against a Respiratory Pneumococcal Challenge in Mice. Clin Vaccine Immunol 2009, 16:636-645. 10.1128/CVI.00395-08, 2681601, 19279169.
11. de Lúcia Hernani M, Ferreira PC, Ferreira DM, Miyaji EN, Ho PL, Oliveira ML. Nasal immunization of mice with Lactobacillus casei expressing the pneumococcal surface protein C primes the immune system and decreases pneumococcal nasopharyngeal colonization in mice. FEMS Immunol Med Microbiol 2011, 14.
12. Oliveira ML, Areas AP, Campos IB, Monedero V, Perez-Martinez G, Miyaji EN, Leite LC, Aires KA, Lee Ho P. Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with Recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbes Infect 2006, 8:1016e1024.
13. Hanniffy SB, Carter AT, Hitchin E, Wells JM. Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J Infect Dis 2007, 195:185e193.
14. Campos IB, Darrieux M, Ferreira DM, Miyaji EN, Silva DA, Arêas AP, Aires KA, Leite LC, Ho PL, Oliveira ML. Nasal immunization of mice with Lactobacillus casei expressing the Pneumococcal Surface Protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge. Microbes Infect 2008, 10:481-8. 10.1016/j.micinf.2008.01.007, 18403234.
15. Green BA, Zhang Y, Masi A, Barniak V, Wetherell M, Smith R, Reddy M, Zhu D. PppA, a surface-exposed protein of Streptococcus pneumoniae, elicits cross- reactive antibodies that reduce colonization in a murine intranasal immunization and challenge model. Infect Immun 2005, 73:981-989. 10.1128/IAI.73.2.981-989.2005, 547003, 15664941.
16. Medina M, Vintiñi E, Villena J, Raya R, Alvarez S. Lactococcus lactis as an adjuvant and delivery vehicle of antigens against pneumococcal respiratory infections. Bioengineered Bugs 2010, 1:313-325. 10.4161/bbug.1.5.12086, 3037581, 21326831.
17. Medina M, Villena J, Vintiñi E, Hebert E, Raya RR, Alvarez S. Nasal immunization with Lactococcus lactis expressing the pneumococcal protective protein A induces protective immunity in mice. Infec Immun 2008, 76:2696-2705.
18. Cangemi de Gutierrez R, Santos V, Nader-Macias ME. Protective effect of intranasally inoculated Lactobacillus fermentum against Streptococcus pneumoniae challenge on the mouse respiratory tract. FEMS Immunol Med Microbiol 2001, 31:187-195. 10.1111/j.1574-695X.2001.tb00519.x, 11720814.
19. Medina M, Villena J, Salva S, Vintiñi E, Langella P, Alvarez S. Nasal administration of Lactococcus lactis improves the local and systemic immune responses against Streptococcus pneumoniae. Microbiol Immunol 2008, 52:399-409. 10.1111/j.1348-0421.2008.00050.x, 18667039.
20. Racedo S, Villena J, Medina M, Agüero G, Rodríguez V, Alvarez S. Lactobacillus casei administration reduces lung injuries in a Streptococcus pneumoniae infection. Microb Infect 2006, 8:2359-2366.
21. Villena J, Racedo S, Agüero G, Bru E, Medina M, Alvarez S. Lactobacillus casei improves resistance to pneumococcal respiratory infection in malnourished mice. J Nutr 2005, 135:1462-1469.
22. Alvarez S, Herrero C, Bru E, Perdigon G. Effect of Lactobacillus casei and yogurt administration on prevention of Pseudomonas aeruginosa infection in young mice. J Food Prot 2001, 64:1768-74.
23. Hirose Y, Murosaki S, Yamamoto Y, Yoshikai Y, Tsuru T. Daily Intake of Heat-Killed Lactobacillus plantarum L-137 Augments Acquired Immunity in Healthy Adults. J Nutr 2006, 136:3069-3073.
24. Li N, Russell WM, Douglas-Escobar M, Hauser N, Lopez M, Neu J. Live and Heat-Killed Lactobacillus rhamnosus GG: Effects on Proinflammatory and Anti-Inflammatory Cytokines/Chemokines in Gastrostomy-Fed Infant Rats. Pedriat Res 2009, 66(2):203-207.
25. Zhang L, Li N, Caicedo R, Neu J. Alive and Dead Lactobacillus rhamnosus GG Decrease Tumor Necrosis Factor-alpha Induced Interleukin-8 Production in Caco-2 Cells. J Nutr 2005, 135:1752-1756.
26. Repa A, Grangette C, Daniel C, Hochreiter R, Hoffmann-Sommergruber K, Thalhamer J, Kraft D, Breiteneder H, Mercenier A, Wiedermann U. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine 2003, 22:87-95. 10.1016/S0264-410X(03)00528-0, 14604575.
27. Walker RI. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 1994, 12:387-400. 10.1016/0264-410X(94)90112-0, 8023545.
28. Wu HY, Nahm MH, Guo Y, Russell MW, Briles DE. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis 1997, 175:839-846. 10.1086/513980, 9086139.
29. Briles DE, Hollingshead SK, King J, Swift A, Braun PA, Park MK, Ferguson LM, Nahm MH, Nabors GS. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 2000, 182:1694-1701. 10.1086/317602, 11069242.
30. Seo JY, Seong SY, Ahn BY, Kwon IC, Chung H, Jeong SY. Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin A encapsulated in microspheres. Infect Immun 2002, 70:1143-1149. 10.1128/IAI.70.3.1143-1149.2002, 127797, 11854194.
31. Daniels CC, Coan P, King J, Hale J, Benton KA, Briles DE, Hollingshead SK. The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis. Infect Immun 2010, 78(5):2163-72. 10.1128/IAI.01199-09, 2863538, 20194601.
32. Medina M, Izquierdo E, Ennahar S, Sanz Y. Differential immunomodulatory properties of Bifidobacterium longum strains: relevance to probiotic selection and clinical applications. Clin Exp Immunol 2007, 150:531-538. 10.1111/j.1365-2249.2007.03522.x, 2219384, 17956582.
33. Twigg HL. Humoral immune defense (antibodies): recent advances. Proc Am Thorac Soc 2005, 2:417-421. Review, 10.1513/pats.200508-089JS, 16322592.
34. Rubin J, McGarry L, Strutton D, Klugman K, Pelton S, Gilmore K, Weinstein M. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 2010, 10:7634-7643.
35. Lambrecht B, Kool M, Willart M, Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009, 21:23-29. 10.1016/j.coi.2009.01.004, 19246182.
36. Bertholet S, Coler R, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30:23-32. 10.1016/j.it.2008.09.006, 19059004.
37. Vintiñi E, Villena J, Alvarez S, Medina M. Administration of a probiotic associated with nasal vaccination with inactivated Lactococcus lactis-PppA induces effective protection against pneumoccocal infection in young mice. Clin Exp Immunol 2010, 159:351-362. 10.1111/j.1365-2249.2009.04056.x, 2819501, 20002449.
38. Villena J, Medina M, Raya R, Alvarez S. Oral immunization with recombinant Lactococcus lactis confers protection against respiratory pneumococcal infection. Can J Microbiol 2008, 54:845-853. 10.1139/W08-077, 18923553.
39. Villena J, Medina M, Vintiñi E, Alvarez S. Stimulation of respiratory immunity by oral administration of Lactococcus lactis. Can J Microbiol 2008, 54:630-638. 10.1139/W08-052, 18772925.
40. Villena J, Barbieri N, Salva S, Herrera M, Alvarez S. Enhanced immune response to pneumococcal infection in malnourished mice nasally treated with heat-killed Lactobacillus casei. Microbiol Immunol 2009, 53:636-646. 10.1111/j.1348-0421.2009.00171.x, 19903264.
41. Hori T, Kiyoshima J, Shida K, Yasui H. Effect of Intranasal Administration of Lactobacillus casei Shirota on Influenza Virus Infection of Upper Respiratory Tract in Mice. Clin Diagn Lab Immunol 2001, 8(3):593-597. 96107, 11329464.
42. Kiyono H, Fukuyama S. NALT-versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 2004, 4:699-710. 10.1038/nri1439, 15343369.
43. Hussell T, Humphreys IR. Nasal vaccination induces protective immunity without immunopathology. Clin Exp Immunol 2002, 130:359-362. 10.1046/j.1365-2249.2002.02038.x, 1906536, 12452823.
44. Perdigón G, Alvarez S, Medina M, Vintiñi E, Roux E. Influence of oral administration of lactic acid bacteria on IgA producing cells associated to bronchus. Int J Immunopathol Pharmacol 1999, 2:97-102.
45. de Moreno de LeBlanc A, Maldonado Galdeano C, Chaves S, Perdigon G. Oral administration of L. casei CRL 431 increases immunity in bronchus and mammary glands. European Journal of inflammation 2005, 3:25-30.
46. Zhang Q, Bernatoniene J, Bagrade L, Paton JC, Mitchell TJ, Hammerschmidt S, Nunez DA, Finn A. Regulation of Production of Mucosal Antibody to Pneumococcal Protein Antigens by T-Cell-Derived Gamma Interferon and Interleukin-10 in Children. Inf Imm 2006, 74:4735-4743.
47. Bejon P, Keating S, Mwacharo J, Kai O, Dunachie S, Walther M, Berthoud T, Lang T, Epstein J, Carucci D, Moris P, Cohen J, Gilbert S, Peshu N, Marsh K, Hill A. Early gamma interferon and interleukin-2 responses to vaccination predict the late resting memory in malaria-naïve and malaria-exposed individuals. Infect Immun 2006, 74:6331-6338. 10.1128/IAI.00774-06, 1695504, 16966412.
48. Foulds K, Wu C, Seder R. Th1 memory: implications for vaccine development. Immunol Rev 2006, 211:58-66. (Review), 10.1111/j.0105-2896.2006.00400.x, 16824117.
49. Lu YJ, Gross J, Bogaert D, Finn A, Bagrade L, Zhang Q, Kolls JK, Srivastava A, Lundgren A, Forte S, Thompson CM, Harney KF, Anderson PW, Lipsitch M, Malley R. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog 2008, 4:e1000159. 10.1371/journal.ppat.1000159, 2528945, 18802458.
50. Zhang Z, Clarke TB, Weiser JN. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Investig 2009, 119:1899-909. 2701860, 19509469.
51. Lin Y, Slight S, Khader S. Th17 cytokines and vaccine-induced immunity. Semin Immunopathol 2010, 32:79-90. 10.1007/s00281-009-0191-2, 2855296, 20112107.
52. Oliveira ML, Miyaji EN, Ferreira DM, Moreno AT, Ferreira PC, Lima FA, Santos FL, Sakauchi MA, Takata CS, Higashi HG, Raw I, Kubrusly FS, Ho PL. Combination of pneumococcal surface protein A (PspA) with whole cellpertussis vaccine increases protection against pneumococcal challenge in mice. PLoS One 2010, 27:5(5):e10863.
53. Detmer A, Glenting J. Live bacterial vaccines-a review and identification of potential hazards. Microb Cell Fact 2006, 5:23. 10.1186/1475-2859-5-23, 1538998, 16796731.